Early data show clinical activity for phenoxodiol

Marshall Edwards, a US drug developer focused on cancer, says that  recent data support the anti-tumor effects of phenoxodiol in advanced  and early-stage prostate cancer.

Presented at the American Society of Clinical Oncology Genitourinary  Cancers Symposium, held in Orlando, Florida, an interim analysis shows  that, among advanced-stage patients, one remains on therapy without  disease progression for more than six months and one had a greater than  50% post-therapy PSA decline, while five in the early-stage cohort had  stable disease for a median time of three months.

"Oral phenoxodiol was very well tolerated with no severe adverse events  reported to date. More importantly, we observed some evidence of  clinical activity, especially in the early-stage disease group, in terms  of holding disease progression in check," said lead researcher Kevin  Kelly. "Further studies evaluating the impact of phenoxodiol on serum  cytokines will be explored at the completion of the trial," he  added.